Abeona Therapeutics

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s lead clinical program is EB-101, its investigational autologous gene-corrected cell therapy for the treatment of recessive dystrophic epidermolysis bullosa, currently in Phase 3 development. The company’s development portfolio also includes AAV-based gene therapies for ocular disorders with high unmet medical needs. Abeona’s novel next-generation AAV capsids are being evaluated to enhance tropism profiles for various debilitating conditions.